Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8⁺ T-Cell Infiltration in Rabbit VX2 Liver Tumor

References

• OmataM, ChengAL, KokudoN, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370.28620797
   PubMed Web of Science ®Google Scholar
• VillanuevaA. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra171326330970190
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.29628281
   PubMed Web of Science ®Google Scholar
• WuX-Z, XieG-R, ChenD. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22(8):1178–1182. doi:10.1111/j.1440-1746.2007.04997.x17559361
   PubMed Web of Science ®Google Scholar
• SergioA, CristoforiC, CardinR, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914–921. doi:10.1111/j.1572-0241.2007.01712.x18177453
   PubMed Web of Science ®Google Scholar
• XiaoE-H, GuoD, BianD-J. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol. 2009;15(36):4582–4586. doi:10.3748/wjg.15.458219777619
   PubMed Web of Science ®Google Scholar
• MalagariK, PomoniM, KelekisA, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541–551. doi:10.1007/s00270-009-9750-019937027
   PubMed Web of Science ®Google Scholar
• BrownKT, DoRK, GonenM, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2016;34(17):2046–2053. doi:10.1200/JCO.2015.64.082126834067
   PubMed Web of Science ®Google Scholar
• FornerA, ReigM, BruixJ. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• LeungHWC, LiuC-F, ChanALF. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. Radiat Oncol. 2016;11:69. doi:10.1186/s13014-016-0644-427193904
   PubMed Web of Science ®Google Scholar
• ParikhND, MarshallVD, SingalAG, et al. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: an analysis of the SEER-Medicare database. Hepatology. 2017;65(1):122–133. doi:10.1002/hep.2888127770556
   PubMed Web of Science ®Google Scholar
• LiX, QiuM, WangS, et al. A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2020;85(3):593–604. doi:10.1007/s00280-020-04031-132008115
   PubMed Web of Science ®Google Scholar
• LiuJ, LiX, ZhangH, et al. Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial. Pharmazie. 2019;74(11):688–693.31739839
   PubMed Web of Science ®Google Scholar
• LinY-S, YangH, DingY, et al. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: results of a Randomized, Multicenter Phase II Trial. Thyroid. 2021;31(4):607–615. doi:10.1089/thy.2020.023532907500
   PubMed Web of Science ®Google Scholar
• QinS, BiF, GuS. et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: a Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol;2021. JCO2100163. doi:10.1200/JCO.21.0016334185551
   PubMed Web of Science ®Google Scholar
• ParvinianA, CasadabanLC, HauckZZ, et al. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. Diagn Interv Radiol. 2015;21(3):235–240. doi:10.5152/dir.2014.1439425835078
   PubMed Web of Science ®Google Scholar
• ShiQ, LuY, HuangS, et al. Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization in vitro, pharmacokinetics and tumor response in vivo. Drug Deliv. 2020;27(1):1301–1307. doi:10.1080/10717544.2020.181888132924634
   PubMed Web of Science ®Google Scholar
• BizeP, DuranR, FuchsK, et al. Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. Radiology. 2016;280(2):425–435. doi:10.1148/radiol.201615036126919561
   PubMed Web of Science ®Google Scholar
• LencioniR, LlovetJM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-124713220175033
   PubMed Web of Science ®Google Scholar
• HongK, KhwajaA, LiapiE, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12(8):2563–2567. doi:10.1158/1078-0432.CCR-05-222516638866
   PubMed Web of Science ®Google Scholar
• MarreroJA, KulikLM, SirlinCB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.2991329624699
   PubMed Web of Science ®Google Scholar
• XieD-Y, RenZ-G, ZhouJ, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-48032832496
   PubMed Web of Science ®Google Scholar
• LiaoY, WangB, HuangZ-L, et al. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study. PLoS One. 2013;8(4):e60444. doi:10.1371/journal.pone.006044423565248
   PubMed Web of Science ®Google Scholar
• AvritscherR, JoN, PolakU, et al. Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2020;43(2):311–321. doi:10.1007/s00270-019-02343-131591689
   PubMed Web of Science ®Google Scholar
• LiuK, ZhangX, XuW, et al. Targeting the vasculature in hepatocellular carcinoma treatment: starving versus normalizing blood supply. Clin Transl Gastroenterol. 2017;8(6):e98. doi:10.1038/ctg.2017.2828617447
   PubMed Web of Science ®Google Scholar
• FukumuraD, KloepperJ, AmoozgarZ, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.2929508855
   PubMed Web of Science ®Google Scholar
• PinterM, Peck-RadosavljevicM, HongK. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48(6):598–609. doi:10.1111/apt.1491330039640
   PubMed Web of Science ®Google Scholar
• KhanKA, KerbelRS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–324. doi:10.1038/nrclinonc.2018.929434333
   PubMed Web of Science ®Google Scholar
• BiF, QinS, GuS, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: an open-label, randomized, multicentre phase trial. 2020 ASCO Annual Meeting Symposium: abstract 4506; 2020.
   Google Scholar
• KimGM, KimMD, KimDY, et al. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: pharmacokinetics and Antitumor Effect. J Vasc Interv Radiol. 2016;27(7):1086–1092. doi:10.1016/j.jvir.2016.02.03227179404
   PubMed Web of Science ®Google Scholar
• ZhouC, YaoQ, ZhangH, et al. Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis. Sci Rep. 2020;10(1):2964. doi:10.1038/s41598-020-59746-132076049
   PubMed Web of Science ®Google Scholar
• LiuL, CaoY, ChenC, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–11858. doi:10.1158/0008-5472.CAN-06-137717178882
   PubMed Web of Science ®Google Scholar
• XiongB, FengG, LuoS, et al. Changes of CD4(+) CD25 (+) regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE. J Huazhong Univ Sci Technolog Med Sci. 2008;28(6):645–648. doi:10.1007/s11596-008-0606-719107357
   PubMedGoogle Scholar
• LiaoJ, XiaoJ, ZhouY, et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep. 2015;12(4):6065–6071. doi:10.3892/mmr.2015.417126239573
   PubMed Web of Science ®Google Scholar
• ZhouW, DengJ, ChenQ, et al. Expression of CD4+CD25+CD127 regulatory T cells and cytokines in peripheral blood of patients with primary liver carcinoma. Int J Med Sci. 2020;17(6):712–719. doi:10.7150/ijms.4408832218692
   PubMed Web of Science ®Google Scholar
• ChuangH-Y, ChangY-F, LiuR-S, et al. Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. PLoS One. 2014;9(10):e109992. doi:10.1371/journal.pone.010999225333973
   PubMed Web of Science ®Google Scholar
• SeidenstickerM, StreitS, NassN, et al. Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model. Diagn Interv Radiol. 2016;22(4):378–384. doi:10.5152/dir.2016.1546227328720
   PubMed Web of Science ®Google Scholar